R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
NCT00137995
Completed
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/22/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +9 locations
Conditions: Lymphoma, Large-Cell, Diffuse
Register for Updates
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
NCT01867710
Completed
The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients. Prednisone will be given at one of three different dose schedules. Dexamethasone will be given at one dose schedule. This will include looking at what side effects occur and how often they occur. In addition the impact of the study drug on quality of life and pain will be evaluated. The study will also col... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/02/2019
Locations: Not set, Aalst, Not set +16 locations
Conditions: Prostate Cancer
Register for Updates
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
NCT01055496
Completed
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2019
Locations: Davis Cancer Pavillion and Shands Medical Plaza, Gainesville, Florida +27 locations
Conditions: Lymphoma, B-Cell
Register for Updates
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00168298
Completed
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2019
Locations: Not set, Houston, Texas +12 locations
Conditions: Macular Edema, Retinal Vein Occlusion
Register for Updates
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
NCT00511706
Completed
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/11/2019
Locations: Not set, Boynton Beach, Florida +8 locations
Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Register for Updates
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
NCT01427751
Completed
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2019
Locations: Not set, Paris, Not set +5 locations
Conditions: Retinal Vein Occlusion, Macular Edema
Register for Updates
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
NCT01492400
Completed
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2019
Locations: Not set, Arlington, Texas +12 locations
Conditions: Macular Edema
Register for Updates
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01846611
Completed
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2019
Locations: Not set, Birmingham, Alabama +141 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Register for Updates
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
NCT03334487
Withdrawn
A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (\>= Grade 3) select treatment-emergent adverse events (TEAEs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2018
Locations: Ironwood Cancer & Res Ctr /ID# 171335, Chandler, Arizona +59 locations
Conditions: Small Cell Lung Cancer
Register for Updates
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
NCT02374060
Completed
To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure will be percent change in central subfield thickness as measured by OCT at 8 weeks. Participants will continue in the study for 24 weeks in order to evaluate relative effects of the 3 treatment strategies on the duration o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2018
Locations: Jules Stein Eye Institute, UCLA, Los Angeles, California +25 locations
Conditions: Macular Edema, Uveitis
Register for Updates
Dexamethasone for Excessive Menstruation
NCT01769820
Completed
This study builds on previous research which has provided compelling evidence that deficient activity of glucocorticoids in the endometrium is a cause of increased menstrual bleeding. This study aims to demonstrate that a glucocorticoid (dexamethasone), already in common use for other conditions, (eg to treat medical conditions such as asthma and rheumatoid arthritis in early pregnancy), will reverse the endometrial glucocorticoid deficiency and as a result reduce menstrual blood loss. The stud... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
10/23/2018
Locations: University of Edinburgh, Edinburgh, Not set
Conditions: Heavy Menstrual Bleeding
Register for Updates
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
NCT01311687
Completed
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2018
Locations: Mayo Clinic, Rochester, Minnesota +93 locations
Conditions: Multiple Myeloma
Register for Updates